Connection

GABRIEL LOPEZ to Drug Carriers

This is a "connection" page, showing publications GABRIEL LOPEZ has written about Drug Carriers.
Connection Strength

1.428
  1. Liposomal polyene antibiotics. Methods Enzymol. 2005; 391:304-13.
    View in: PubMed
    Score: 0.220
  2. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med (Berl). 1996 Oct; 74(10):623-8.
    View in: PubMed
    Score: 0.124
  3. The past, present, and future uses of liposomes in treating infectious diseases. Immunopharmacol Immunotoxicol. 1995 Feb; 17(1):1-15.
    View in: PubMed
    Score: 0.110
  4. Nanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.
    View in: PubMed
    Score: 0.101
  5. The influence of serum lipoproteins on the pharmacokinetics and pharmacodynamics of lipophilic drugs and drug carriers. Arch Med Res. 1993; 24(4):395-401.
    View in: PubMed
    Score: 0.096
  6. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm. 2007 Aug 16; 341(1-2):221-9.
    View in: PubMed
    Score: 0.064
  7. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005 May 20; 23(15):3495-501.
    View in: PubMed
    Score: 0.056
  8. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci. 2003 Jan-Apr; 6(1):67-83.
    View in: PubMed
    Score: 0.048
  9. Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2002 May; 43(5):933-41.
    View in: PubMed
    Score: 0.046
  10. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma. 1998 Jul; 30(3-4):367-79.
    View in: PubMed
    Score: 0.035
  11. Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin Infect Dis. 1996 Nov; 23(5):1126-38.
    View in: PubMed
    Score: 0.031
  12. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 01; 87(9):3650-4.
    View in: PubMed
    Score: 0.030
  13. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma. 1996 Mar; 21(1-2):93-7.
    View in: PubMed
    Score: 0.030
  14. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994 Sep; 38(9):2224-6.
    View in: PubMed
    Score: 0.027
  15. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res. 1994 Aug; 18(8):587-96.
    View in: PubMed
    Score: 0.027
  16. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood. 1994 Jul 15; 84(2):601-7.
    View in: PubMed
    Score: 0.027
  17. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci. 1994 Jul; 83(7):1006-10.
    View in: PubMed
    Score: 0.027
  18. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy. 1994 Jul-Aug; 40(4):256-64.
    View in: PubMed
    Score: 0.027
  19. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother. 1994 Feb; 38(2):223-7.
    View in: PubMed
    Score: 0.026
  20. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. J Drug Target. 1994; 2(5):373-80.
    View in: PubMed
    Score: 0.026
  21. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis. 1993 Jul; 168(1):253-4.
    View in: PubMed
    Score: 0.025
  22. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine. Drug Metab Dispos. 1991 Nov-Dec; 19(6):1147-51.
    View in: PubMed
    Score: 0.022
  23. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis. 1991 Nov; 164(5):1003-6.
    View in: PubMed
    Score: 0.022
  24. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med. 1991 Apr 15; 114(8):664-6.
    View in: PubMed
    Score: 0.021
  25. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis. 1990 Mar; 161(3):562-6.
    View in: PubMed
    Score: 0.020
  26. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov; 149(11):2533-6.
    View in: PubMed
    Score: 0.019
  27. A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation. Sel Cancer Ther. 1989; 5(3):113-7.
    View in: PubMed
    Score: 0.018
  28. Liposomes in infectious diseases: present and future. Curr Clin Top Infect Dis. 1989; 10:241-53.
    View in: PubMed
    Score: 0.018
  29. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7.
    View in: PubMed
    Score: 0.014
  30. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. 2003 May-Aug; 6(2):292-301.
    View in: PubMed
    Score: 0.012
  31. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer. 2002 Dec 15; 95(12):2555-61.
    View in: PubMed
    Score: 0.012
  32. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1237-45.
    View in: PubMed
    Score: 0.011
  33. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 01; 94(7):2230-5.
    View in: PubMed
    Score: 0.010
  34. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. 1997 Oct; 41(10):2238-43.
    View in: PubMed
    Score: 0.008
  35. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother. 1994 Feb; 38(2):356-9.
    View in: PubMed
    Score: 0.006
  36. Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex. Leuk Lymphoma. 1993 Mar; 9(4-5):385-92.
    View in: PubMed
    Score: 0.006
  37. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res. 1990 Jul 15; 50(14):4254-9.
    View in: PubMed
    Score: 0.005
  38. Inhibition of HIV replication by liposomal encapsulated amphotericin B. Antiviral Res. 1989 Apr; 11(3):119-25.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.